What's breaking now, across thousands of outlets.
Investors are beginning to turn cautious on biotechnology stocks as a rapid rise in Treasury yields dents the appeal for shares of companies that are often viewed as risky all-or-nothing bets on breakthrough medical treatments.
We haven't written up this one. Bloomberg has the full story — the link below goes straight to it.
Is Archer the millionaire-maker of this generation?
Here are Thursday's biggest calls on Wall Street.
Norway’s $2.3 trillion sovereign wealth fund lost $29.7 billion in Q3 2026 as rising interest rates hurt bond returns, despite small gains in stocks.
American reported record third quarter revenues but unlike Delta and United, it could not make a profit.
Digital trust services provider eMudhra on Thursday said that it would voluntarily withdraw from the global SSL/TLS certificate business, following an incident where its certificates were found to…
